🔗 Share this article

As the United States proceeds with unprecedented changes to its vaccination recommendations, one figure has emerged in a surprising turn: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by questioning Covid shots in the pandemic and has concentrated on potential deaths following Covid vaccination in her short time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Program

Health officials were set to unveil radical changes to the childhood vaccine schedule earlier this month, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US out of step with many the international standard with no evidence for improved outcomes. This reveal has been pushed back until the new year.

Rather than the top vaccines chief, Høeg is listed to speak at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth person to run the division this year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a tighter collaboration between the drug and biologics branches as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for ending certain childhood vaccine recommendations in the US so as to align more in line with Denmark's approach, a country with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – usually the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, regulation or leadership, which has been standard for former leaders of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in running a sizeable institution. She has no expertise in drug approvals.”

Former directors of CBER would “be deeply familiar with legal statutes and the science of drug development”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an vast workload at the agency, Woodcock emphasized.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and every single one need to be supervised,” Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant management aspect to the job, which supervises more than 5,000 staff members. “It is a massive management job, if you perform it correctly,” she said.

Official Statement and Disputed Programs

In response to questions about Høeg’s qualifications and whether this appointment indicates more teamwork among FDA leaders on immunizations, a press secretary said that the “questions stem from incorrect presumptions”.

“Her experience is consistent with the duties of her role,” the official explained, noting the time Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As acting director, Dr. Høeg takes over the agency head's recently launched fast-track approval initiative, a disputed one-day therapy clearance system that reportedly worried her preceding directors. “By what process are these therapies being chosen for this voucher program? Who makes the calls?” Howard asked. “There is a lot of secrecy happening at the FDA right now.”

Broadly speaking, he said, “the agency seems to be moving towards laxer rules of all drugs, except for vaccines.”

Public History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if problematic, track record, Howard said. She released a study using unconfirmed volunteer-provided data to determine the incidence of myocarditis following Covid immunization. She advised the state of Florida top health official Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Part of her “wish list” for the new government included changing rules for novel immunizations and discontinuing “optional” vaccines, she remarked after the election on a podcast. At the FDA, Høeg has according to sources proposed barring young men from getting Covid vaccines.

“She’s an thorough ideologue who starts off with her beliefs and tailors the evidence to fit the evidence in a extremely misleading, dishonest fashion,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|